![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/biotheryx-announces-first-patient-dosed-in-phase-1-clinical-trial-of-btx-9341-a-first-in-class-dual-bifunctional-degrader-of-cdk46-as-a-monotherapy-and-in-combination-with-fulvestrant-for-hrher2--breast-cancer-302198738.html
https://www.prnewswire.com/news-releases/biovaxys-appoints-christopher-cherry-as-chief-financial-officer-302131360.html
https://www.prnewswire.com/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108919.html
https://www.prnewswire.com/news-releases/biovaxys-announces-allowance-of-dpx-formulation-patent-for-the-united-states-and-filing-of-additional-international-patent-applications-for-phase-1-dpx-surmage-302107159.html
https://www.prnewswire.com/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302083463.html
https://www.prnewswire.com/news-releases/biovaxys-announces-allowance-of-dpx-related-patent-for-japan-and-filing-of-additional-international-patent-applications-302079691.html
https://www.prnewswire.com/news-releases/biovaxys-acquires-all-intellectual-property-immunotherapeutics-platform-technology-and-clinical-stage-assets-of-the-former-imv-inc-302059809.html
https://www.indianpharmapost.com/news/biovaxys-executes-loi-for-major-immunotherapeutics-technology-acquisition-15066
https://www.prnewswire.com/news-releases/biovaxys-executes-letter-of-intent-for-major-immunotherapeutics-technology-acquisition-302021828.html
https://www.prnewswire.com/news-releases/biovaxys-in-non-binding-discussions-for-major-immunotherapeutics-technology-acquisition-302013317.html